Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine neuropsychiatric care by leveraging neurobiology to develop personalized and highly effective treatment options. Through our AI-enabled biomarker platform, we combine rich sources of information on patients' b... Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine neuropsychiatric care by leveraging neurobiology to develop personalized and highly effective treatment options. Through our AI-enabled biomarker platform, we combine rich sources of information on patients' brain activity and behavior to better identify which patients are more likely to respond to our novel product candidates. 더 보기
– Data generated from Alto’s precision psychiatry platform and clinical-stage product candidates highlighted across three poster presentations and a panel discussion – – New preclinical data from...
– Topline data from two MDD trials expected in the first half of 2025: Phase 2b trial of ALTO-300 as an adjunctive treatment and Phase 2a trial of ALTO-203 in patients with anhedonia – –...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.12 | 2.79069767442 | 4.3 | 4.64 | 4.09 | 230494 | 4.35851562 | CS |
4 | 0.66 | 17.5531914894 | 3.76 | 4.6971 | 3.66 | 231314 | 4.28928784 | CS |
12 | 0.29 | 7.02179176755 | 4.13 | 4.98 | 3.56 | 391091 | 4.1672609 | CS |
26 | -10.97 | -71.2800519818 | 15.39 | 17.55 | 3.56 | 510476 | 7.29334503 | CS |
52 | -17.58 | -79.9090909091 | 22 | 24 | 3.56 | 359168 | 9.14973874 | CS |
156 | -17.58 | -79.9090909091 | 22 | 24 | 3.56 | 359168 | 9.14973874 | CS |
260 | -17.58 | -79.9090909091 | 22 | 24 | 3.56 | 359168 | 9.14973874 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관